Coronavirus | Russias RDIF talking with Indian firms on making vaccine

 thehindu.com  09/16/2020 17:39:05 

Russias sovereign wealth fund RDIF is in discussion with Indian firms to manufacture the COVID-19 vaccine Sputnik V that is currently undergoing trials.

We would confirm that we are in talks with a number of Indian companies on Sputnik V manufacturing, but cannot disclose [their] names as yet, a spokesperson for the Russian Direct Investment Fund (RDIF) said.

Responding to queries, after RDIF announced a partnership with Dr. Reddys for clinical trials and distribution of the vaccine in India, he said details of tie-ups with other companies would follow soon.

Under the partnership, Dr. Reddys has the right to buy the first 100 million doses of the vaccine, he said. On pricing of the vaccine, the spokesperson said the pricing was yet to be announced. RDIF has said previously it was not aiming at making a profit, just covering costs, he said.

Developed by Gamaleya National Research Institute of Epidemiology and Microbiology, Sputnik V is the worlds first registered vaccine against COVID-19 based on the human adenoviral vectors platform.

In August, the vaccine was registered by Russias Health Ministry and declared ready for use, it triggering a debate on its efficacy amid a rush to go through the clinical trials. Putting his weight behind, Russian President Vladimir Putin was quoted by international media as saying the vaccine underwent necessary tests and was proven efficient. One of his daughters was already inoculated, the President had said.

The partnership of RDIF with Dr. Reddys follows those involving many vaccine manufacturers in India, since the COVID-19 outbreak, with institutions both in India and abroad working on vaccine candidates for the virus.

The list includes Serum Institute of India, Bharat Biotech, Biological E, Aurobindo Pharma and Indian Immunologicals. For Dr.Reddys the partnership comes amid its acquisition earlier this year of select divisions of Wockhardt, including a manufacturing facility in Baddi, Himachal Pradesh. The business acquired included vaccines too.

Global export hub

Besides a big domestic market, India is a strong player globally in the field of vaccines. In FY20, vaccine exports amounted to $878.64 million, accounting for 4.27% of total pharma exports of $20.58 billion.

Its manufacturing prowess is evident from the fact that About 70% WHO vaccines and 90% of measles shots are sourced from India.

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Support Quality Journalism

Dear subscriber,

Thank you!

Your support for our journalism is invaluable. Its a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath

« Go back